How do you preserve fertility and testicular function while on TRT?

The short answer

Testosterone replacement shuts down your own production: the brain stops signaling the testes, which shrinks them and impairs sperm production — exogenous testosterone is a leading, often-preventable cause of male infertility. The fix is to keep the testes working with hCG (which mimics LH), planned from the start, with kisspeptin as an emerging upstream option. If fertility matters, this isn't optional — it's the core peptide layer of any TRT plan.

Evidence tier: Tier 1–2 for the TRT→suppression biology and hCG's role; Tier 3 for kisspeptin in this specific use. This is education, not medical advice — fertility-on-TRT is firmly clinician territory.

The key points:

• TRT suppresses the HPG axis — your testes stop producing testosterone and sperm
• hCG mimics LH — keeps the testes active and preserves intratesticular testosterone/fertility
• Plan before starting — preserving function is easier than recovering it
• Kisspeptin is emerging — acts higher up the axis; promising but less established here

This is a spoke of our TRT and peptides hub.

Why does TRT cause the problem in the first place?

Evidence tier: 1–2 — well-established endocrinology.

The mechanism is the whole story. Your testes are run by the HPG axis: the hypothalamus releases GnRH, the pituitary responds with LH and FSH, and those hormones drive the testes to make both testosterone and sperm. Sperm production specifically depends on a very high concentration of testosterone inside the testes (intratesticular testosterone), far above blood levels — and that's produced locally under LH stimulation. When you inject exogenous testosterone, your brain senses plenty of testosterone and switches off GnRH/LH/FSH. Blood testosterone is fine (that's the point of TRT), but the testes lose their LH signal, intratesticular testosterone collapses, and spermatogenesis fails.

The clinical reality is stark: TRT impairs sperm production and a large fraction of men become azoospermic (no measurable sperm) on it, making exogenous testosterone a well-documented and largely preventable cause of male infertility (Kohn 2016; managing TRT/AAS suppression). The testes also typically shrink (atrophy) as they go dormant. This isn't a rare side effect — it's the expected physiological consequence of how TRT works, which is exactly why fertility preservation has to be a deliberate part of the plan rather than an afterthought.

How does hCG protect fertility on TRT?

Evidence tier: 1–2 — direct human evidence.

hCG (human chorionic gonadotropin) is the workhorse solution, and it works because it mimics LH. Even while exogenous testosterone has switched off your own LH, hCG provides the testes with the LH-like signal they need to keep producing intratesticular testosterone — preserving the local environment spermatogenesis requires. The human evidence is solid for this specific use: concomitant low-dose hCG alongside testosterone maintains intratesticular testosterone in men with gonadotropin suppression (Coviello 2005), and men on TRT plus hCG preserved spermatogenesis versus the suppression seen on TRT alone (Hsieh 2013).

Practically, this is why fertility-conscious TRT protocols pair testosterone with low-dose hCG (commonly small doses a few times weekly), and why hCG is also used to keep the testes responsive so recovery is easier if a man later comes off TRT. It also addresses testicular atrophy (the testes stay active and don't shrink as much). The key point is timing: maintaining function with hCG from the start is far more reliable than trying to restart a fully-shut-down axis later. Anyone on or starting TRT who values fertility should be discussing hCG with their prescriber — it's established medicine, not a fringe add-on.

What does fertility-preserving TRT look like in practice?

Evidence tier: 2–3 — established practice, individualized dosing.

In a fertility-conscious protocol, the testosterone and the hCG run together from day one rather than hCG being bolted on after a problem appears. The practical pattern most clinicians use is low-dose hCG several times weekly alongside the testosterone, with the dose titrated to the individual — enough to keep the testes active and intratesticular testosterone in a useful range, without driving estradiol or other effects too high. Some men also add an FSH-containing product if FSH-driven sperm parameters need support, since hCG mainly substitutes for LH. The point isn't a fixed recipe — it's that fertility is designed into the regimen instead of being a rescue mission later.

Monitoring is what makes this work. A fertility-minded plan tracks not just blood testosterone (the usual TRT marker) but the things that actually reflect fertility: a semen analysis as the ground truth on sperm production, plus testicular exam/size and estradiol so the hCG dose can be tuned. Because everyone's axis responds differently — age, baseline fertility, and how long they've been suppressed all matter — the numbers guide the adjustments. And because hCG, FSH, and testosterone are all prescription medicines with real interactions, this belongs with a clinician comfortable with male fertility rather than a self-directed protocol pieced together from forums.

Where does kisspeptin fit?

Evidence tier: 3 — promising, less established for this use.

Kisspeptin is the newer, more upstream option. Where hCG acts at the bottom of the axis (directly on the testes, mimicking LH), kisspeptin acts near the top — it's a key trigger for GnRH release, effectively the master switch that initiates the whole HPG cascade. That makes it mechanistically interesting for stimulating the axis more "physiologically," and kisspeptin has genuine research behind it in reproductive medicine (kisspeptin and the reproductive axis).

The honest caveat is that kisspeptin's use specifically for fertility preservation on TRT is far less established than hCG — it's an emerging tool with promising biology rather than a proven protocol, and dosing/availability are less worked out. For most men today, hCG is the evidence-backed choice and kisspeptin is the interesting frontier to watch. There's also overlap with how kisspeptin is studied for libido and broader HPG function, which we touch on in the TRT and sexual health and sexual-health peptides guides. The reasonable framing: if you want a fertility-preservation peptide on TRT now, that's hCG; kisspeptin is the upstream option that may grow into a bigger role.

What if you're already on TRT and want fertility back?

Evidence tier: 2–3 — restart protocols are real but variable.

If the axis is already suppressed and you want fertility, recovery is possible but neither instant nor guaranteed. Restart protocols — typically stopping testosterone and using hCG (to wake the testes) often combined with a SERM like clomiphene or tamoxifen (to boost LH/FSH from the pituitary), sometimes with FSH — are used to restore spermatogenesis (fertility preservation in hypogonadism). Recovery time varies from months to over a year, and depends on age, how long you were suppressed, baseline fertility, and whether you used hCG along the way.

This is why the recurring message is plan ahead: maintaining function with hCG from the start is far more reliable than restarting a long-dormant axis, and some men don't fully recover. Anyone on TRT who might want children — even uncertainly — is best served by either running hCG alongside TRT from the beginning or banking sperm before starting. And every part of this (restart drugs, hCG, SERMs, FSH) is prescription medicine requiring a clinician, ideally one comfortable with male fertility — it's not a DIY gray-market project, because the stakes are permanent and the protocols need monitoring.

Limitations

This is educational content, not medical advice.

• TRT-induced infertility can be lasting — not everyone recovers fully, even with restart protocols.
• hCG, SERMs, and FSH are prescription medicines requiring clinician management and monitoring.
• Kisspeptin for fertility-on-TRT is emerging, not an established protocol like hCG.
• Plan fertility before starting TRT — preservation beats attempted recovery.
• Sperm banking is the most reliable safeguard if fertility is a priority.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

TRT works by raising blood testosterone, but that signals the brain to shut down the HPG axis — collapsing the intratesticular testosterone that sperm production needs, and making exogenous testosterone a leading preventable cause of male infertility. The established fix is hCG, which mimics LH to keep the testes producing and preserves fertility, with strong human evidence; kisspeptin is a promising upstream option that's less established for this use. The decisive factor is timing: protect function from the start with hCG (or bank sperm) rather than trying to restart a dormant axis later — and do all of it with a clinician.

Related on this site

• TRT and peptides: how they fit together
• TRT and sexual health: when peptides help
• Peptides for sexual health: PT-141, kisspeptin, oxytocin
• Sexual health pillar
• Peptide safety and sourcing guide
• Our evidence-tier framework

References

• Kohn TP, Louis MR, et al. 2016. Exogenous testosterone: a preventable cause of male infertility. PMID 26813847 — TRT and infertility.
• Coviello AD, et al. 2005. Low-dose hCG maintains intratesticular testosterone in men with testosterone-induced gonadotropin suppression. PMID 15713727 — hCG maintains intratesticular testosterone.
• Hsieh TC, et al. 2013. Concomitant intramuscular hCG preserves spermatogenesis in men undergoing TRT. PMID 23260550 — hCG preserves fertility on TRT.
• 2022. Understanding and managing suppression of spermatogenesis caused by TRT and AAS. PMID 35783920 — suppression and restart approaches.
• Dhillo WS, et al. 2020. Kisspeptin and the reproductive (HPG) axis. PMID 33196464 — kisspeptin's upstream role.